Ensysce Biosciences (ENSC) Free Cash Flow (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Free Cash Flow of -$1.9 million for Q3 2025, down 82.9% year-over-year from -$10.9 million in Q3 2024, and up 31.06% quarter-over-quarter from -$2.7 million in Q2 2025.
Ensysce Biosciences (ENSC) Free Cash Flow (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Free Cash Flow for 8 consecutive years, with -$1.9 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Free Cash Flow fell 82.9% year-over-year to -$1.9 million; the TTM figure through Dec 2025 stood at -$6.3 million (up 16.29% YoY), while the FY2024 annual figure was -$7.5 million, up 30.4% from the prior year.
- Free Cash Flow advanced to -$1.9 million in Q3 2025 per ENSC's latest filing, from -$2.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$132312.0 in Q2 2021 and bottomed at -$6.7 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$2.7 million across 5 years, with a median of -$2.7 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 3256.08% — and 2023, when it soared 66.3%.
- Ensysce Biosciences' Free Cash Flow stood at -$3.8 million in 2021, then gained by 12.53% to -$3.3 million in 2022, then surged by 45.33% to -$1.8 million in 2023, then soared by 57.59% to -$764090.0 in 2024, then sank by 144.24% to -$1.9 million in 2025.
- Business Quant data shows ENSC's Free Cash Flow at -$1.9 million in Q3 2025, -$2.7 million in Q2 2025, and -$1.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.87 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Dec 31, 2024 | -764,090.00 |
| Dec 31, 2024 | -764,090.00 |
| Sep 30, 2024 | -1.02 Mn |
| Sep 30, 2024 | -1.02 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Jun 30, 2023 | -3.11 Mn |
| Jun 30, 2023 | -3.11 Mn |